Niagen Bioscience, Inc.
NAGE
$7.38
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 29.13M | 25.58M | 22.74M | 22.15M | 21.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.13M | 25.58M | 22.74M | 22.15M | 21.20M |
| Cost of Revenue | 10.93M | 9.34M | 9.05M | 8.70M | 8.26M |
| Gross Profit | 18.20M | 16.24M | 13.69M | 13.46M | 12.94M |
| SG&A Expenses | 9.77M | 13.35M | 12.63M | 12.09M | 11.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.01M | 23.98M | 23.00M | 22.88M | 21.36M |
| Operating Income | 7.11M | 1.60M | -256.00K | -731.00K | -168.00K |
| Income Before Tax | 7.48M | 1.88M | -15.00K | -492.00K | 114.00K |
| Income Tax Expenses | 305.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.18M | 1.88M | -15.00K | -492.00K | 114.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.18M | 1.88M | -15.00K | -492.00K | 114.00K |
| EBIT | 7.11M | 1.60M | -256.00K | -731.00K | -168.00K |
| EBITDA | 7.30M | 1.80M | -49.00K | -515.00K | 48.00K |
| EPS Basic | 0.09 | 0.02 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.06 | 0.02 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.09 | 0.02 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.06 | 0.02 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 76.95M | 75.97M | 75.56M | 75.23M | 75.12M |
| Average Diluted Shares Outstanding | 81.68M | 77.77M | 75.56M | 75.23M | 75.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |